{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:57:20Z","timestamp":1791496640149,"version":"4.3.4"},"reference-count":56,"publisher":"SAGE Publications","issue":"1_suppl","license":[{"start":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T00:00:00Z","timestamp":1443571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Educ"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The pathophysiology of diabetes has historically focused on alterations in insulin secretion and function; however, diabetes involves multiple hormonal alterations, including abnormal regulation of amylin. This review discusses the physiologic functions of amylin in glucose homeostasis and the rationale for amylin replacement in type 1 and 2 diabetes. The use of pramlintide, a synthetic amylin analog, is also discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Amylin, formed primarily in pancreatic islet \u03b2 cells, is cosecreted with insulin in response to caloric intake. Patients with type 1 diabetes have lower baseline amylin serum concentrations, and amylin response to caloric intake is absent. Patients with type 2 diabetes requiring insulin also have a diminished amylin response to caloric intake, potentially related to the degree of \u03b2-cell impairment. Key physiologic functions of amylin in maintaining glucose homeostasis include suppressing glucagon release in response to caloric intake, delaying the rate of gastric emptying, and stimulating the satiety center in the brain to limit caloric intake. Pramlintide is indicated for adults with type 1 and 2 diabetes who have not achieved adequate glucose control despite optimal insulin therapy. As an adjunct to insulin therapy, pramlintide demonstrated significant reductions in A1C in patients with type 1 and 2 diabetes, with favorable effects on body weight. It is administered subcutaneously before each major meal. There is an increased risk of hypoglycemia with insulin when used in combination with pramlintide. Other adverse effects may include nausea, vomiting, anorexia, reduced appetite, and headache. Proper patient selection and education are essential to successful pramlintide use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0145721715607642","type":"journal-article","created":{"date-parts":[[2015,9,30]],"date-time":"2015-09-30T21:38:39Z","timestamp":1443649119000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":76,"title":["Role of Amylin in Type 1 and Type 2 Diabetes"],"prefix":"10.1177","volume":"41","author":[{"given":"Laura","family":"Hieronymus","sequence":"first","affiliation":[{"name":"DiabetesCare &amp; Communications, Lexington, KY, USA (Dr Hieronymus)"},{"name":"Baptist Health-Lexington, KY, USA (Dr Griffin)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Griffin","sequence":"additional","affiliation":[{"name":"DiabetesCare &amp; Communications, Lexington, KY, USA (Dr Hieronymus)"},{"name":"Baptist Health-Lexington, KY, USA (Dr Griffin)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,9,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-S009"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197108192850806"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/826706"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00042.2009"},{"key":"e_1_3_3_6_2","first-page":"101S","article-title":"The physiology of amylin and insulin: maintaining the balance between glucose secretion and glucose uptake","volume":"32","author":"Martin C","year":"2006","unstructured":"Martin C. The physiology of amylin and insulin: maintaining the balance between glucose secretion and glucose uptake. Diabetes Educ. 2006;32(suppl 3):101S-104S.","journal-title":"Diabetes Educ"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/014572179902500310"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.23.8628"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5036"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-15-2-163"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-0405"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2006.1858"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90785-2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/42.4.576"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8227(92)90074-2"},{"key":"e_1_3_3_16_2","first-page":"A149","article-title":"Amylin response following Sustacal ingestion is diminished in type II diabetic patients treated with insulin","volume":"39","author":"Fineman MS","year":"1996","unstructured":"Fineman MS, Giotta MP, Thompson RG, Kolterman OG, Koda JE. Amylin response following Sustacal ingestion is diminished in type II diabetic patients treated with insulin. Diabetologia. 1996;39(suppl 1):A149.","journal-title":"Diabetologia"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00060793-199708000-00006"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.5.715"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90170-0"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.2001.280.3.E443"},{"key":"e_1_3_3_21_2","first-page":"1083","article-title":"Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus","volume":"81","author":"Nyholm B","year":"1996","unstructured":"Nyholm B, Moller N, Gravholt CH, . Acute effects of the human amylin analog AC137 on basal and insulin-stimulated euglycemic and hypoglycemic fuel metabolism in patients with insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1996;81:1083-1089.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00400683"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2006.263"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199604)37:4<231::AID-DDR5>3.0.CO;2-M"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/diab.47.1.93"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2000.278.6.G946"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2002.00311.x"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389450053174596"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/0031-9384(95)02067-5"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00213.2004"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.physbeh.2010.04.012"},{"key":"e_1_3_3_32_2","first-page":"9","article-title":"A new look at glucose control: the case for therapy with insulin and an amylin analog","volume":"16","author":"Edelman SV","year":"1998","unstructured":"Edelman SV, Kruger DF. A new look at glucose control: the case for therapy with insulin and an amylin analog. Pract Diabetol. 1998;16:9-14.","journal-title":"Pract Diabetol"},{"key":"e_1_3_3_33_2","unstructured":"Symlin (pramlintide acetate) injection for subcutaneous use: US prescribing information [package insert]. Wilmington DE: AstraZeneca Pharmaceuticals LP; 2015."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1053\/meta.2002.32022"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.11.3074"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(99)90232-9"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.18.8.1179"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0042"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2004.01319.x"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.25.4.724"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP.15.3.229"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150252924094"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-0589"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2003"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1732-4"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00217.2007"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-0029"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2005-837662"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2004.00417.x"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.23.2.124"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2011.00652.x"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.26.3.134"},{"key":"e_1_3_3_54_2","unstructured":"Apidra (insulin glulisine [rDNA origin] injection): US prescribing information [package insert]. Bridgewater NJ: Sanofi-Aventis US LLC; 2015."},{"key":"e_1_3_3_55_2","unstructured":"Humalog Mix50\/50 (insulin lispro injection suspension): US prescribing information [package insert]. Indianapolis IN: Eli Lilly & Co; 2015."},{"key":"e_1_3_3_56_2","unstructured":"Novolog (insulin aspart [rDNA origin] injection): US prescribing information [package insert]. Plainsboro NJ: Novo Nordisk Inc; 2015."},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.29.1.17"}],"container-title":["The Diabetes Educator"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0145721715607642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0145721715607642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0145721715607642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:09:17Z","timestamp":1777648157000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0145721715607642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,30]]},"references-count":56,"journal-issue":{"issue":"1_suppl","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1177\/0145721715607642"],"URL":"https:\/\/doi.org\/10.1177\/0145721715607642","relation":{},"ISSN":["0145-7217","1554-6063"],"issn-type":[{"value":"0145-7217","type":"print"},{"value":"1554-6063","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,30]]}}}